Bionature seeks to identify new technologies that will enable the diagnosis, prevention and treatment of major diseases. The main focus is the design and development of novel drug candidates for the treatment of cancer and neurological disease.

The Company’s strategic objective is to in-license, protect and commercially exploit intellectual property rights that arise from the research activities of its scientists and their associates. Bionature aims to continually generate novel therapeutic agents of large clinical importance and value. In effect, Bionature operates as a small early stage technology incubator, developing and nurturing R&D projects with significant market potential.

Bionature leverages its partnerships with academic centers to create synergy in applied and clinical research in the biomedical sciences, and in the development, testing and marketing of innovative pharmaceuticals and other biomedical products. Bionature is actively looking for licensing partners.